Biomarin Pharmaceuticals (BMRN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 105,527 | 348,901 | 395,474 | 426,218 | 185,686 |
| Depreciation Amortization | 15,956 | 74,756 | 55,424 | 37,915 | 20,707 |
| Income taxes - deferred | 9,220 | 48,738 | 48,125 | 61,771 | 28,429 |
| Accounts receivable | -7,159 | -228,054 | -107,378 | -156,124 | -57,590 |
| Other Working Capital | 39,068 | -293,660 | -129,608 | -248,535 | -90,462 |
| Other Operating Activity | 58,039 | 877,313 | 466,313 | 238,420 | 87,624 |
| Operating Cash Flow | $220,651 | $827,994 | $728,350 | $359,665 | $174,394 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 741,485 | -18,074 | -18,715 | -6,695 | -11,470 |
| PPE Investments | -20,923 | -103,038 | -62,316 | -33,869 | -16,768 |
| Net Acquisitions | N/A | -285,193 | -285,193 | N/A | N/A |
| Purchase Sale Intangibles | N/A | -7,937 | -5,569 | -266 | N/A |
| Other Investing Activity | 4,966 | -7,937 | -5,569 | -266 | 0 |
| Investing Cash Flow | $725,528 | $-414,242 | $-371,793 | $-40,830 | $-28,238 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 850,000 | N/A | N/A | N/A | N/A |
| Common Stock Issued | N/A | 14,460 | 7,714 | 7,707 | N/A |
| Other Financing Activity | -36,833 | -56,854 | -53,265 | -51,089 | -38,779 |
| Financing Cash Flow | $813,167 | $-42,394 | $-45,551 | $-43,382 | $-38,779 |
| Exchange Rate Effect | 1,410 | -2,521 | -3,740 | -4,479 | -1,416 |
| Beginning Cash Position | 1,311,679 | 942,842 | 942,842 | 942,842 | 942,842 |
| End Cash Position | 3,072,435 | 1,311,679 | 1,250,108 | 1,213,816 | 1,048,803 |
| Net Cash Flow | $1,760,756 | $368,837 | $307,266 | $270,974 | $105,961 |
| Free Cash Flow | |||||
| Operating Cash Flow | 220,651 | 827,994 | 728,350 | 359,665 | 174,394 |
| Capital Expenditure | -20,923 | -103,038 | -62,316 | -33,869 | -16,768 |
| Free Cash Flow | 199,728 | 724,956 | 666,034 | 325,796 | 157,626 |